Intellia Therapeutics, Inc.
NTLA- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652130
In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 329 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.
Holders of 5% or more of NTLA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Intellia Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 12.27%14.2M shares | +1.17 ppfrom 11.10% | Nov 4, 20252 filings | Feb 3, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.20%8.45M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| State Street Corp | 13G | 5.50%6.42M shares | +1.10 ppfrom 4.40% | May 13, 20252 filings | Feb 9, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.30%6.27M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.03%5.95M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
14 Schedule 13D and 13G filings on Intellia Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Apr 30, 202610:23 AM ET | Vanguard Capital Management LLC | 13G | 5.03%5.95M shares | New | Mar 31, 2026 | SEC |
| Apr 29, 20261:48 PM ET | Vanguard Portfolio Management LLC | 13G | 5.30%6.27M shares | New | Mar 31, 2026 | SEC |
| Mar 27, 20269:51 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −11.23 ppfrom 11.23%Below 5% | Mar 13, 2026 | SEC |
| Feb 12, 20262:39 PM ET | Goldman Sachs Group Incand 1 other | 13G/A | 2.70%3.16M shares | −2.40 ppfrom 5.10%Below 5% | Dec 31, 2025 | SEC |
| Feb 11, 20261:18 PM ET | Contrarius Investment Management Ltdand 1 other | 13G/A | 0.60%714.5K shares | −4.90 ppfrom 5.50%Below 5% | Dec 31, 2025 | SEC |
| Feb 9, 20266:42 AM ET | State Street Corp | 13G | 5.50%6.42M shares | +1.10 ppfrom 4.40% | Dec 31, 2025 | SEC |
| Feb 3, 202611:35 AM ET | ARK Investment Management LLCand 1 otherSuperinvestorARK Invest | 13G/A | 12.27%14.2M shares | +1.17 ppfrom 11.10% | Dec 31, 2025 | SEC |
| Jan 30, 20262:16 PM ET | Vanguard Group Inc | 13G/A | 11.23%13.0M shares | +1.23 ppfrom 10.00% | Dec 31, 2025 | SEC |
| Nov 12, 20253:55 PM ET | Goldman Sachs Group Incand 1 other | 13G | 5.10%5.50M shares | New | Sep 30, 2025 | SEC |
| Nov 12, 20251:47 PM ET | Contrarius Investment Management Ltdand 1 other | 13G | 5.50%5.89M shares | New | Sep 30, 2025 | SEC |
| Nov 4, 20254:50 PM ET | ARK Investment Management LLCand 1 otherSuperinvestorARK Invest | 13G/A | 11.10%11.9M shares | – | Sep 30, 2025 | SEC |
| May 13, 202511:22 AM ET | State Street Corp | 13G | 4.40%4.51M shares | NewBelow 5% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 8.20%8.45M shares | – | Mar 31, 2025 | SEC |
| Jan 8, 202511:29 AM ET | Vanguard Group Inc | 13G/A | 10.00%10.2M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Intellia Therapeutics, Inc. shares.
No Form 144 notices for Intellia Therapeutics, Inc. are on file.